Joaquín V. Arribas López

(DOB December 12th, 1964)

Education

1987	Grade in Biochemistry, Autonomous University of Madrid
1992	Ph D in Cellular and Molecular Biology, Autonomous University of Madrid
2015	Program on High Management of Health Institutions, IESE Business School

Present Positions

2007	ICREA Research Professor
2007	Associate Professor, Department of Biochemistry and Molecular Biology, Universidad Autónoma de Barcelona
2010	Director, Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO)
2020	Research Director, PSMAR. Director, IMIM

Research and Professional Experience

1988-1992	Graduate student, Autonomous University of Madrid. Advisor: Dr. José G. Castaño. Project: Proteasome and autoinmunity
Jun-Oct 1990	Frederick Cancer Research Facility, Frederick, Maryland, U.S.A. Advisor: Dr. Luis Parada. Project: Cloning and sequencing of murine trk proto-oncogen
1993-1997	Postdoctoral Researcher, Memorial Sloan-Kettering Cancer center & Howard Hughes Medical Institute, New York. Principal Investigator: Joan Massagué. Project: Activation of transmembrane growth factors
1997-2007	Research Faculty, Vall d'Hebron University Hospital, Catalan Institute of Health
2003-2010	Head, Medical Oncology Research Program, Vall d'Hebron University Hospital, Catalan Institute of Health
2017-2020	Scientific Director, CIBERONC

Table of Contents

Funding	2
Invited Conferences, oral presentations and organizing committees	8
Patents	11
Thesis supervision	13
Current positions of former postdoctoral laboratory members	14
Miscellanea	15
Publications	16

Funding

NOTE: Only competitive grant awards in which Dr. Arribas is principal investigator or co-principal investigator are listed. In addition, the Arribas laboratory receives funding from several pharmaceutical companies to develop translational research projects. In fact, approximately 25% of the current budget of his laboratory comes from research agreements with Roche, Novartis, Celgene, Menarini, Synthon and Mnemo.

1. Title: Overcoming Drug Resistance in HER2-Positive Breast Cancer,
Funding body: National Institutes of Health
Institution: Vall d'Hebron Institue of Oncology (VHIO)
Reference: R01CA244601-01
Duration: 2020 - 2025
Amount: 2.451.574$ (57.688 $ correspond to the group led by Dr. Arribas)

2. Title: Redirection of T cells against HER2-driven tumors
Funding body: Asociación Española Contra el Cáncer (AECC)
Institution: Vall d'Hebron Institue of Oncology (VHIO)
Reference: GCAEC19017ARRI
Duration: November 2019 - November 2024
Amount: € 1,000,000 (500,000 correspond to the group led by Dr. Arribas)

3. Title: Immunotherapy against HER2-positive tumors
Funding body: Instituto de Salud Carlos III (www.isciii.es)
Reference: PI19/01181
Amount: € 378,000
Duration: January 2020 -December 2022

4. Title: Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system
Funding body: Breast Cancer Research Foundation
Reference:
Amount: $ 700,000 (€576,000)
Duration: October 2018-October 2021

5. Title: SGR 2017-2019
Funding body: Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR/Fons Europeus de Desenvolupament Regional (FEDER) 2014-2020
Reference:
Amount: € 42,000
Duration: 2018 - 2021

6. Title: EDIReX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts
Funding body: European Union. Horizon 2020 call H2020-INFRAIA-2016-2017 "Integrating activities for starting communities"
Reference:
Amount: € 143,868.18€ (Consortium: 5.156.198,75€)
Duration: 2017-October 2022

7. Title: Clinical impact of intratumor heterogeneity in mestastatic breast cancer – Cancer Core Europe
Funding body: European Union (TRANSCAN)
Reference: AC15/00062
Amount: € 99,825
Duration: January 2016-December 2018

8. Title: CIBER-ONC -Breast Cancer Program
Funding body: Instituto de Salud Carlos III (www.isciii.es)
Reference: CB16/12/00449
Amount: € 300,000

Duration: January 2017-December 2021

9. Title: COLOSSUS
Funding body: European Union (Horizon 2020)
Reference: SC1-PM-02-2017
Amount: € 442,306.25 (for our group; € 5,996,359,5total)
Duration: January 2018-December 2023

10. Title: Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system
Funding body: Breast Cancer Research Foundation (BCRF) (http://www.bcrfcure.org)
Reference: BCRF-17-008
Amount: $ 250,000
Duration: January 2017-December 2018

11. Title: Immunotherapy Against HER2-positive Breast and Gastric Cancers
Funding body: Instituto de Salud Carlos III (www.isciii.es)
Reference: PI17
Amount: € 290,620
Duration: January 2017-December 2019

12. Title: Immunotherapy against p95HER2 positive breast cancer
Funding body: Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR/Fons Europeus de Desenvolupament Regional (FEDER) 2014-2020
Reference: 2016 PROD 00108
Amount: € 100,000
Duration: 26/07/2017 - 26/01/2019

13. Title: Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system
Funding body: Breast Cancer Research Foundation (BCRF) (http://www.bcrfcure.org)
Reference: —
Amount: $ 250,000
Duration: October 2016 - October 2017

14. Title: Clinical impact of intratumor heterogeneity in mestastatic breast cancer – Cancer Core Europe
Funding body: European Comission
Reference: AC15/00062
Amount: € 99.825
Duration: January 2016 - December 2018

15. Title: Targeting Oncogene-Induced Sensescence in Breast Cancer
Funding body: Breast Cancer Research Foundation (BCRF) (http://www.bcrfcure.org)
Reference: —
Amount: $ 250,000
Duration: October 2015 - October 2016

16. Title: Anticipating resistances to novel anti-HER2 therapies
Funding body: Breast Cancer Research Foundation (BCRF) (http://www.bcrfcure.org)
Reference: —
Amount: $ 250,000
Duration: October 2014 - October 2015

17. Title: Therapies against p95HER2-positive breast cancers and cellular senescence induced by p95HER2
Funding body: Instituto de Salud Carlos III (www.isciii.es)
Reference: PI1202536
Amount: € 510,620
Duration: January 2013-December 2015

18. Title: Thematic Network of Cooperative Research in Cancer (http://www.rticc.org)
Funding body: Instituto de Salud Carlos III (www.isciii.es)
Reference: RD12/0036/0042
Amount: € 92,575
Duration: January 2013-December 2014

19. Title: Premature cellular aging and breast cancer
Funding body: Sandra Ibarra Foundation (http://www.fundacionsandraibarra.org)
Reference: —
Amount: € 25,000
Duration: March 2013 – March 2014

20. Title: HER2-induced cellular senescence in breast cancer progression and treatment
Funding body: Breast Cancer Research Foundation (BCRF) (http://www.bcrfcure.org)
Reference: —
Amount: $ 240,000
Duration: October 2012-October 2013

21. Title: Novel strategies to treat HER2-positive breast cancers
Funding body: Spanish Association Against Cancer (https://www.aecc.es)
Reference: —
Amount: $1,200,000
Duration: September 2012-September 2017

22. Title: Treatment the hyperactivation of HER2 in breast cancers
Funding body: AVON Cosmetics Foundation (http://www.avon.es/PRSuite/aecc.page)
Reference: —
Amount: € 285,333
Duration: May 2012 - May 2015
Title: Functional characterization of novel factors mediating the oncogenic activity of HER2. Role in the progression of breast cancer

23. Funding body: Breast Cancer Research Foundation (BCRF) (http://www.bcrfcure.org)
Reference: —
Amount: $ 500,000
Duration: October 2010- October 2012.

24. Title: Research Collaboration Agreement (Glaxo Smith Kline)
Funding body: Glaxo Smith Kline
Reference: —
Amount: $ 500.000
Duration: October 2009- December 2012

25. Title: Novel factors and mechanisms mediating the oncogenic activity of HER2
Funding body: Breast Cancer Research Foundation (BCRF) (http://www.bcrfcure.org)
Reference: —
Amount: $ 250,000
Duration: October 2009- October 2010

26. Title: Technologic development of diagnostic and/or therapeutic monoclonal antibodies against the HER2 receptor and its truncated variants
Funding body: Genome Spain Foundation
Reference: —
Amount: € 276,300
Duration: May 2009- December 2011

27. Title: Grants for consolidated research groups
Funding body: Agencia de Gestió d'Ajuts Universitaris i de Recerca (http://www10.gencat.cat/agaur_web)
Reference: 2009SGR328

Amount: € 44,720
Duration: January 2009- January 2014

28. Title: Carboxy-terminal fragments of HER2 in the progression and treatment of breast cancer
Funding body: Instituto de Salud Carlos III (www.isciii.es)
Reference: PI081154
Amount: € 794,970
Duration: January 2009- January 2013

29. Title: Metastasis in breast tumors expressing 611-CTF of HER2: mechanisms and therapeutic strategies
Funding body: Breast Cancer Research Foundation (BCRF) (http://www.bcrfcure.org)
Reference: —
Amount: $ 250.000
Duration: October 2008- October 2009

30. Title: Thematic Network of Cooperative Research in Cancer (http://www.rticc.org)
Funding body: Instituto de Salud Carlos III (www.isciii.es)
Reference: RD06/0020/0022
Amount: € 1,666,587
Duration: January 2007-December 2012

31. Title: Identification and characterization of mechanisms and factors involved in the intracellular trafficking of ADAM17
Funding body: Fundación Mutua Madrileña (http://www.fundacionmutua.es)
Reference: —
Amount: € 43,200
Duration: May 2007- May 2010

32. Title: Identification of factors and mechanisms leading to metastasis in breast tumors expressing HER2 Carboxy Terminal Fragments
Funding body: Breast Cancer Research Foundation (BCRF) (http://www.bcrfcure.org)
Amount: $ 250.000
Duration: October 2007- October 2008.

33. Title: Grants for consolidated research groups
Funding body: Agencia de Gestió d'Ajuts Universitaris i de Recerca (http://www10.gencat.cat/agaur_web)
Reference: 2005SGR00612
Amount: $ 36,600
Duration: January 2006- January 2009

34. Title: Generation and characterization of transgenic mice expressing carboxy-terminal fragment of the HER2 oncogene in mammary glands
Funding body: Spanish Ministry of Education and Science
Reference: SAF2005-03939
Amount: € 232,050
Duration: January 2006- January 2009

35. Title: Identification and characterization of the mechanism of tumorogenesis mediated by HER2 carboxy terminal fragments
Funding body: Fundació la Marató TV3. (http://www.tv3.cat/marato/en/)
Reference: 05010
Amount: € 248,750
Duration: January 2006- January 2009

36. Title: Thematic Network of Cooperative Research in Cancer (http://www.rticc.org)
Funding body: Instituto de Salud Carlos III
Reference: PI051658
Amount: € 196,350

Duration: January 2006- December 2006

37. Title: Functional and structural characterization of a novel product of the proto-oncogene HER2. Therapeutic implications in breast cancer
Funding body: Spanish Association Against Cancer (https://www.aecc.es)
Reference: —
Amount: € 300.000
Duration: February 2005- February 2008

38. Title: Identification of the degradome of the metalloprotease disintegrin TACE: relevance in breast cancer progression
Funding body: "La Caixa" Foundation
Reference: BM05-208-00
Amount: 137.000 euros
Duration: May 2005 – May 2008

39. Title: Signaling and Membrane Trafficking in Transformation and Differentiation
Funding body: European Commission (STREP)
Reference: FP6-503228
Amount: € 234,000
Duration: January 2004- December 2006.

40. Title: Cancer Genomics. Tumor genotyping
Funding body: Instituto de Salud Carlos III (www.isciii.es)
Reference: C03/10
Amount: € 1,002,319 euros
Duration: January 2003- December 2005

41. Title: Grants for consolidated research groups
Funding body: Agencia de Gestió d'Ajuts Universitaris i de Recerca (http://www10.gencat.cat/agaur_web)
Reference: 2002SGR00019
Amount: € 48,000
Duration: January 2003- December 2005

42. Title: EMBO Special Grant
Funding body: Spanish Ministry of Education and Science
Reference: 2001-5069-E
Amount: € 44,500
Duration: January 2003- December 2003

43. Title: Role of the shedding of HER2-receptor ligands in tumor progression. Papel del shedding de los ligandos de receptores HER en el desarrollo y progresión tumoral
Funding body: Instituto de Salud Carlos III (www.isciii.es)
Reference: PI021003
Amount: € 51,175
Duration: January 2003-December 2005

44. Title: Characterization and identification of the components of the machinery of the transport of NMDA receptor to the cell surface
Funding body: Funding body: Fundació la Marató TV3 (http://www.tv3.cat/marato/en/)
Reference: 01810
Amount: € 101,198
Duration: January 2002- December 2004

45. Title: Shedding of pro-Transforming Growth Factor-alpha role of metalloprotease-disintegrins and pro-protein convertases
Funding body: EMBO Young Investigator Programme
Reference: 450
Amount: € 90,000

Duration: January 2002- December 2004

46. Title: Identification and characterization of the mechanism of transport of proTGF-alpha to the cell surface
Funding body: Spanish Ministry of Education and Science
Reference: SAF2000-0203
Amount: 162.624 euros (27.104.000 pesetas)
Duration: January 2001-December 2003

47. Title: Regulation of the Adamalysins and the ubiquitin-proteasome in the proteolytic processing of the betaAPP
Funding body: "La Caixa" Foundation (http://obrasocial.lacaixa.es)
Reference: 99/0020-1
Amount: € 51,750 euros (8.625.000 pesetas)
Duration: January 1998- January 2001

48. Title: Role of adamlysins in the generation of the Abeta peptide
Funding body: Fundació la Marató TV3 (http://www.tv3.cat/marato/en/)
Reference: 036/97
Amount: € 94,239
Duration: January 1998- January 2001

49. Title: Identification and characterization of the factors involved in the activated cleavage of transmembrane growth factors
Funding body: Spanish Ministry of Education and Science
Reference:SAF97-0229
Amount: € 113,022 (18.837.000 pesetas)
Duration: January 1997- December 2000

Invited Conferences, oral presentations and organizing committees

(selected among more than 200 participations)

1. Meeting: 2020 Mammary Gland Biology GRC
Venue: Il Ciocco, Italy
Date: June 7th-12th, 2020
Participation: Invited Conference
Title: Safe redirection of cytotoxic lymphocytes agains breast cancer cells

2. Meeting: Mobilizing specific T cells against cancer
Venue: INSERM, Paris
Date: Jul 5th, 2019
Participation: Invited Conference
Title: Redirection of T-cells against HER2-postive cancers

3. Meeting: Cancer and the immune system
Venue: Bellairs Research Institute, Holetown, Barbados
Date: Jan 20th-27th, 2017
Participation: Invited Conference
Title: Immunotherapy against HER2-postive breast cancer

4. Meeting: Towards Predictive Cancer Models, Vall d'Hebron Insitute of Oncology
Venue: Vall d'Hebron Insitute of Oncology, Barcelona
Date: May 26th-27th, 2016
Participation: Co-Organizer with Dr. Laura Soucek
http://www.vhio.net/en/symposia-conferences/

5. Meeting: Cancer Therapeutic Resistence: Progress and Perspectives. B-Debate
Venue: CaixaForum, Barcelona
Date: April 7th-8th, 2016
Participation: Co-Organizer with Dr. Miquel Angel Pujana
http://www.bdebate.org

6. Meeting: Cell Communication in Translational Research
Venue: Weizmann Institute of Science, Israel
Date: January 22nd-23rd, 2015
Participation: Co-Organizer with Dr. Irit Sagi
Title: Targeting intercellular communication during breast cancer progression
http://wws.weizmann.ac.il/conferences/CCTR2015/program

7. Meeting: Gordon Research Conference on Matrix Metalloproteinases on Regulated Proteolysis of Cell Surface Proteins
Venue: Ventura CA.
Date: March 30th- April 4th, 2014
Participation: Invited conference
Title: Ectodomain Shedding During Oncogene-Induced Senescence

8. Meeting: Gordon Research Conference on Matrix Metalloproteinases
Venue: Lucca, Barga, Italy
Date: May 19th-24th, 2014
Participation: Invited conference
Title: ADAM17 mediates the protumorigenic effect of p95HER2-induced senescent cells

9. Meeting: 46th Sandbjerg meeting on membrane transport
Venue: Sandbjerg Estate, Sønderborg, Denmark,
Date: May 12th -14th, 2014
Participation: Invited conference
Title: Protein ectodomain shedding during oncogene-induced senescence

10. Meeting: Global Breast Cancer Conference

Venue: Seoul, Korea
Date: October 5th - 7th, 2011
Participation: Invited conference
Title: HER2 Pathway Biology. Focusing on p95HER2,.

11. Meeting: International Symposium on Intracellular Proteolysis and Cancer
Venue: Valencia, Spain
Date: October 26th, 2011
Participation: Invited conference
Title: Proteolytic remodeling of the cell surface during breast cancer progression and

12. Meeting: Gordon Research Conference on Regulated Proteolysis of Cell Surface Proteins
Venue: Davidson, NC, USA
Date: July 10th-15th, 2011
Participation: Chairman, session on Factors that influence ADAM-dependent processing

13. Meeting: CNIO Frontiers Meetings. Breast Cancer
Venue: CNIO, Madrid, Spain
Date: February 7th-t9th, 2011
Participation: Organizer
Title: Hyperactivation of HER2 and anti-HER2 therapies

14. Meeting: 5th General Meeting of the International Proteolysis Society
Venue: Patras, Greece
Date: October, 21st-23rd 2007
Participation: Invited conference
Title: Proteomic identification and characterization of ADAM substrates

15. Meeting: Gordon Research Conference on Matrix Matrix Metalloprotease
Venue: Il Ciocco, Italy
Date: June 6th-7th, 2007
Participation: Invited conference
Title: Identification and characterization of novel ADAM and ADAMTS substrates

16. Meeting: Metzincin Metalloproteases in Health and Diseases
Venue: Ascona, Switzerland,
Date: September 24th-27th, 2006
Participation: Invited conference
Title: Proteomic identification and characterization of ADAM substrates

17. Meeting: 3rd Annual Symposium on Anti-Signaling Strategies in Human Neoplasia
Venue: Barcelona, Spain
Date: September 16th, 2004
Participation: Invited conference and chairman
Title: Characterization of a novel product of the oncogene ErbB2

18. Meeting: Gordon Research Conference on Matrix Metalloproteases
Venue: Big Sky, MT, USA
Date: Agust 18th-21^{2t}, 2003
Participation: Invited conference
Title: Role of TACE in EGFR-Ligand Activation and Tumor Development

19. Meeting: Inaugural Conference, XII National Congress on Bioenergetics and Biomembranes
Venue: Querétaro, Mexico
Date: November 17th-20tth, 2001
Participation: Invited inaugural conference
Title: Biosynthesis and shedding of proTGF-alpha, a prototypical ligand of the Epidermal Growth Factor Receptor

20. Meeting: 26th European Peptide Symposium

Venue: Montpellier, France
Date: September 10th-14th, 2000.
Participation: Plenary Lecture,
Title: Role of protein ectodomain shedding in biological functions

21. Meeting: 11th UK Adhesion Meeting
Venue: London, UK
Date: September 5th 2000
Participation: Invited conference and chairman
Title: Protein ectodomain shedding in the absence of TACE

22. Meeting: Gordon Research Conference on Matrix Metalloproteases
Venue: New London, New Hampshire, USA
Date: Agust 8th-10tth, 1999
Participation: Invited conference
Title: PDZ proteins and intracellular trafficking

23. Meeting: Biochemical Society Meeting, Symposium on Membrane Protein Secretases
Venue: Leicester, UK
Date: September 26th-28th, 1998
Participation: Invited conference
Title: Mechanisms controlling the shedding of transmembrane molecules

Patents

1. Title: CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR P95HER2 AND USES THEREOF
   Inventors: Joaquin Arribas; Irene Rius; Macarena Roman; Alena Gros; Carlos Alberto Fajardo, Christian Klein, Ekkehard Moessner.
   Priority: 28/05/2020 EP20382457.8
   Date of filling: 28/05/2020
   Application number: 20382457.8
   Priority country: European Patent Application
   Designated contracting states: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
   Date of publication of application:
   Publication number:
   Date of publication and mention of the grant of the patent:
   Year granted:
   Patent holding body: Vall d'Hebron Institut d'Oncologia (VHIO), Institució Catalana de Recerca i Estudis Avançats (ICREA)
   Extended:
   Companies exploiting it: Pending to execute an agreement with Mnemo Therpeutics

2. Title: Bispecific T cell activating antigen binding molecules
   Inventors: Marina Bacac, Anne Freimoser-Grundschober, Sylvia Herter, Christian Klein, Joaquín Arribas, Rocío Vicario
   Priority date: Sept, 30th, 2016
   Application number: EP 16191933.7
   Priority country: European Patent Application
   Date of publication:
   Designated contracting states: -
   Designated extensiton states: -
   Year granted: -
   Patent holding body: F. Hoffmann-La Roche AG
   Countries extended: Europe
   Companies exploiting it: F. Hoffmann-La Roche AG

3. Title: ANTIBODIES AGAINST HER2 TRUNCATED VARIANT CTF-611
   Inventors: Joaquin Arribas; Kim Pedersen; Davide Angellini; Josep Lluis Parra; Josep Baselga
   Priority: 07/12/2009 EP 0930183.5
   Date of filling: 07/10/2010
   Application number: 10193969.2
   Priority country: European Patent Application
   Designated contracting states: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
   Date of publication of application: 24/08/2011 Bulletin 2011/34
   Publication number: EP2360187B1
   Date of publication and mention of the grant of the patent: 20/04/2016 Bulletin 2016/16
   Year granted: 2016
   Patent holding body: Vall d'Hebron Institut d'Oncologia (VHIO), Institució Catalana de Recerca i Estudis Avançats (ICREA)
   Extended: Europe, United States, Japan
   Us patent application
      Date of filling: 06/12/2010
      Application number: 12/961,004
      Publication Date: 09/06/2011
      Publication Number: US 2011/0135653A1
   Companies exploiting it: GSK until 2019. Pending to be licensed to Innovent. Only active in USA.

4. Title: Method for diagnosing cancers expressing the HER2 receptor or its truncated variants
   Inventors: Arribas J, Parra-Palau JL, Pedersen, K, Laos S, Angellini PD, Baselga, J
   Priority: 08/06/2008 P200801652

International filling date: 05/06/2009
Application number: 09772265.6
International application number (patent cooperation treaty - pct): PCT/EP2009/056976
US application number: 12479035
Priority country: Spain
Designated states: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW.
Regions: ARIPO (BW, GH GM, KE, LS MW NA SD SL SZ TZ UG ZM ZW, Eurasian (AM AZ BY KG KZ MD RU TJ TM, European (AT, BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR) OAPI (BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG).
Companies exploiting it: GSK until 2019. Pending to be licensed to Innovent. Only active in USA.

Thesis supervision

1. Title: T cell redirection as immunotherapeutic approach against HER2-positive breast cancer
Author: Irene Rius
University: Autonomous University of Barcelona
Faculty: Medicine
Rank: Cum Laude. Pioneer Award 2020
Year: 2019

2. Title: Targeting the Mek1/2-Erk1/2 signaling pathway in pancreatic cancer
Author: Faiz Bilal Espejo
University: Autonomous University of Barcelona
Faculty: Medicine
Rank: Cum Laude
Year: 2019

3. Title: Mechanisms of resistance to TDM-1 in HER2-positive breast cancer
Author: Junjie Zhang
University: Autonomous University of Barcelona
Faculty: Medicine
Rank: Cum Laude
Year: 2018

4. Title: Immunotherapy against HER2-positive breast cance
Author: Rocío Vicario
University: Autonomous University of Barcelona
Faculty: Medicine
Rank: Cum Laude
Year: 2017

5. Title: Mechanisms behind the oncogene-induced senescence (OIS) - oncogene-induced apoptosis (OIA) decision in cells expressing p95HER2
Author: Cristina Bernadó Morales
University: University of Barcelona
Faculty: Pharmacy
Rank: Cum Laude
Year: 2015

6. Title: Hyper-activation of HER2 through the production of carboxy-terminal fragments
Author: Pier Davide Angelini
University: Autonomous University of Barcelona
Faculty: Biology
Rank: Cum Laude
Year: 2014

7. Title: Role of the intracellular domain of TACE/Adam17 on the regulation of its catalytic activity
Author: Maria Teresa Villanueva de la Torre
University: Autonomous University of Barcelona
Faculty: Biology
Rank: Cum Laude
Year: 2007

8. Title: Characterization of the degradoma of Adam17: role of endocytosis on the role of pro-TGF-alpha activity and identification of novel metaloprotease sustrates
Author: Joan Josep Bech Serra
University: Autonomous University of Barcelona
Faculty: Biology
Rank: Cum Laude

Year: 2006

9. Title: Novel mechanisms of tumorogenesis driven by the proto-oncogen HER2: Therapeutic implications in breast cancer
Author: Judit Anido Folgueira
University: University of Barcelona
Faculty: Biology
Rank: Cum Laude
Year: 2006

10. Title: Intracellular trafficking and activation of the metalloprotease Adam17/TACE
Author: Soraya Ruiz Paz
University: University of Barcelona
Faculty: Biology
Rank: Cum Laude
Year: 2005

11. Title: Shedding of the transforming growth factor-alpha during tumor generation and progression. PDZ proteins involved in the intracellular transport of proTFG-alpha
Author: Maria Borrell Pagés
University: University of Barcelona
Faculty: Biology
Rank: Cum Laude
Year: 2002

12. Title: Intracellular trafficking and shedding of the transforming growth factor-alpha.
Author: Anna Merlos Suárez
University: University of Barcelona
Faculty: Biology
Rank: Cum Laude
Year: 2001

Current positions of former postdoctoral laboratory members

More twenty former postdocs that have finished their work at the Arribas laboratory have followed scientific careers. One is the General Director of the Department of Innovation and Public Research (Regional Government of Galicia, Spain), two work managing research projects in pharmaceutical companies (J. Uriach & Cia, Novartis, Amgen), two are assistant professors (University of Barcelona and University Rovira I Virgili, Tarragona, Spain,) three are staff Scientists (Center of Molecular Biology “Severo Ochoa”, Madrid; Neuroscience Institute, Alicante, Spain; and the Technologic Center form Nutrition and Health, Reus, Spain) and four are postodoctoral fellows in different labs around the world (VHIO, Barcelona; VIB, Leuven, Albert Einstein MedNew York).

Miscellanea

2019 - Present	Chairman of the PLBIO Evaluation committee. INCa (France).
2009 - Present	Member of the External Scientific Committee, Instituto de Investigación Hospital Universitario 12 de Octubre, Madrid (I12+i (www.imas12.es)
2009 - Present	Member of the External Scientific Committee, Instituto de Investigación Hospital Universitario La Paz, Madrid (IdiPaz (2017www.idipaz.es))
2017 – 2020	Scientific Director, CIBERONC (https://www.ciberonc.es)
2018 - 2020	Chairman of the External Scientific Committee, Instituto Hospital del Mar de d'Investigaciones Médicas (www.imim.es)
2012 - 2016	Coordinator of the Breast Cancer Programme within the Spanish Network of Cooperative Cancer Research (RTICC) (http://www.rticc.org).
2006 - 2016	Member of the Executive Committee, Cancer Research Network, Instituto de Salud Carlos III (http://www.isciii.es)
2002 - present	Dr. Arribas group was designated "Consolidated Group" by the Department of Universities, Research and Information (DURSI), Generalitat de Cataluña (Catalan Government).
2008 - 2011	Scientific representative (Spain) in EATRIS (European Advanced Translational Research Infraestructure in Medicine) (www.eatris.eu)
2005 - 2018	Member of the Editorial Board. The Journal of Biological Chemistry
2004 - 2011	President of the Commission for the evaluation of research project proposals on Cancer. Fondo de Investigación Sanitaria (Health Research Fund), Insituto de Salud Carlos III ("Carlos III" Health Institute)
2003	Beckman Coulter Award to the Best Young Spanish Investigator in Biochemistry and Molecular Biology. Spanish Society of Biochemistry and Molecular Biology (SEBBM).
2002 - present.	Reviewer of grants for the "The Wellcome Trust" (United Kingdom), the "Swiss Cancer League" (Switzerland), AIRC - Associazione Italiana per la Ricerca sul Cancro I AIRC (Italy), and the Institut National du Cancer, INCa (France).
2002-2006	President of the Scientific Council. Vall d'Hebron University Hospital Research Institute.
2002-2005	Scientific coordinator of the Node Vall d'Hebron, Network of Cancer Centers supported by the Instituto de Salud Carlos III (http://www.isciii.es)
2001	Selected to participate in the YIP program (Young Investigator Program) promoted by the European Molecular Biology Organization (EMBO) (http://www.embo.org/projects/yip/index.html).
1998 -present	Member of the Spanish Society of Biochemistry and Molecular Biology (SEBBM).
1996 - present	Reviewer of papers for the following journals: Nature Medicine, Nature Cell Biol, Cancer Cell, Cell Reports, J Biol Chem, Eur J Biochem, J Cell Sci, EMBO J, J Cell Biol, Gene Dev, Exp. Cell Res, Can Res, Clin Can Res, Nature Cancer, Science Traslational Medicine

Publications

2021

1. Arenas, E. J., Martínez-Sabadell, A., Rius Ruiz, I., Román Alonso, M., Escorihuela, M., Luque, A., Fajardo, C. A, Gros, A., Klein, C. **Arribas, J.** Resistance to HER2-TCB (T cell bispecfic) and -CAR (chimeric antigen receptor) through JAK2 downmodulation (2021). **Nature Comm**, accepted.

Collaborations

2. Loo Yau, H., Bell, E., Ettayebi, I., Campos de Almeida, F., Boukhaled, G. M., Shen, S. Y., Allard, D., Morancho, B., Marhon, S. A., Ishak, C. A., Gonzaga, I., Medina, T., Singhania, R., Chakravarthy, A, Chen, R., Mehdipour, P., Pommey, S., Klein, C., Amarante-Mendes, G., Roulois, D., **Arribas, J.**, Stagg, J. & D. De Carvalho, D. DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T-cells (2021) **Molecular Cell**, accepted.

3. Sanz-Moreno, A., Palomeras, P., Pedersen, K., Morancho, B., Pascual, T., Galván, P., Benítez, S., Gomez-Miragaya, J., Ciscar, M., Jimenez, M., Pernas, S., Petit, A., Soler-Monsó, M. T., Viñas, G., Alsaleem, M., Rakha, E. A., Green, A., R., Santamaria, P. G., Mulder, C., Lemeer, S., Arribas, J., Prat, A., Puig, T., Gonzalez-Suarez, E. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer (2021) **Breast Cancer Res**, accepted

2020

4. Cortés, J., Perez García, J. M., Llombart Cussac, A., Curigliano, G., El Saghir, N. S., Cardoso, F., Barrios, C. H., Wagle, S., Roman, J., Harbeck, N., Eniu, A., Kaufman, P. A., Tabernero, J., García Estévez, L., Schmid, P. & **Arribas, J.** Enhancing global access to cancer medicines. CA Cancer J Clin 70, 105-124 (2020).

5. Nadal-Serrano, M., Morancho, B., Escriva de Romaní, S., Morales, C. B., Luque, A., Escorihuela, M., Espinosa-Bravo, M., Peg, V., Dijcks, F. A., Dokter, W. H. A., Cortés, J., Saura, C. & **Arribas, J.** The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers 12, 670–14 (2020).

6. Serrano, C., Vivancos, A., López-Pousa, A., Matito, J., Mancuso, F. M., Valverde, C., Quiroga, S., Landolfi, S., Castro, S., Dopazo, C., Sebio, A., Virgili, A. C., Menso, M. M., Martín-Broto, J., Sansó, M., García-Valverde, A., Rosell, J., Fletcher, J. A., George, S., Carles, J. & **Arribas, J.** Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer 5;20(1):99 (2020).

Collaborations

7. Ferronato, M.J., Nadal Serrano, M., Arenas Lahuerta, E.J., Bernadó Morales, C., Paolillo, G., Martinez-Sabadell Aliguer, A., Santalla, H., Mascaró, M., Vitale, C., Fall, Y., **Arribas, J.**, Facchinetti, M. M., Curino, A. C. Vitamin D analogues exhibit antineoplastic activity in breast cancer patient-derived xenograft cells. J Steroid Biochem Mol Biol. 105735 (2020). Aug 9;105735. doi: 10.1016/j.jsbmb.2020.105735. Online ahead of print.

8. Gris-Oliver, A., Palafox, M., Monserrat, L., Brasó-Maristany, F., Òdena, A., Sánchez-Guixé, M., Ibrahim, Y. H., Villacampa, G., Grueso, J., Parés, M., Guzman, M., Rodríguez, O., Bruna, A., Hirst, C. S., Barnicle, A., de Bruin, E. C., Reddy, A., Schiavon, G., **Arribas, J.**, Mills, G. B., Caldas, C., Dienstmann, R., Prat, A., Nuciforo, P., Razavi, P., Scaltriti, M., Turner, N. C., Saura, C., Davies, B. R., Oliveira, M. & Serra, V. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clin Cancer Res 26(14):3720-3731 (2020).

9. Mateo, L., Duran-Frigola, M., Gris-Oliver, A., Palafox, M., Scaltriti, M., Razavi, P., Chandarlapaty, S., Arribas, J., Bellet, M., Serra, V. & Aloy, P. Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine 12, 78–23 (2020).

10. García-Valverde, A., Rosell, J., Serna, G., Valverde, C., Carles, J., Nuciforo, P., Fletcher, J. A., **Arribas, J.**, Politz, O. & Serrano, C. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics 19, 1289–1297 (2020).

11. Cebrià-Costa, J. P., Pascual-Reguant, L., Gonzalez-Perez, A., Serra-Bardenys, G., Querol, J., Cosín, M., Verde, G., Cigliano, R. A., Sanseverino, W., Segura-Bayona, S., Iturbide, A., Andreu, D., Nuciforo, P., Bernadó Morales, C., Rodilla, V., **Arribas, J.**, Yelamos, J., de Herreros, A. G., Stracker, T. H. & Peiró, S. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. Oncogene 39, 79–121(2020).

2019

12. Identification and characterization of Cardiac Glycosides as a novel class of broad spectrum senolytic compounds. Triana-Martínez, F., Picallos-Rabina, P., Da Silva-Álvarez, S., Pietrocola, F., Llanos, S., Rodilla, V., Soprano, E., Pedrosa, P., Ferreirós, A., Barradas, A., Hernández-González, F., Lalinde, M., Prats, N., Bernadó, C., González, P., Gómez, M., Ikonomopoulou, M., Fernández-Marcos, P. J., García-Caballero, T., del Pino, P., **Arribas, J.**, Vidal, A., González-Barcia, M., Serrano, M., Loza, M. I., Domínguez, E., Collado, M. (2019) Nat Commun, 10(1):4731

13. Gomez-Miragaya, J., Díaz-Navarro, A., Tonda, R., Beltran, S., Palomero, L., Palafox, M., Dobrolecki, L., Vasaikar, S., Huang, C., Zhang, B., Wulf, G., Muñoz, P., Paré, L., Serra, V., Prat, A., Bruna, A., Caldas, C., **Arribas, J.**, Balmaña, J., Cruz, C., Pujana, M. A., Lewis, M., Puente, X., Gonzalez-Suarez, E. Chromosome 12p amplification in triple-negative breast cancer is associated with emergent docetaxel resistance and carboplatin sensitivity (2019) Cancer Research 79, 4258-4270.

14. Merlino, G., Fiascarelli, A., Bigioni, M., Bressan, A., Carrisi, C., Bellarosa, D., Bugianesi, R., Manno, R., Bernadó Morales, C., **Arribas, J.**, Dusek, R. L., Attanasio, N., Ackroyd, J. E., Bisht, A., Huy Pham, P., Anderson, A., Swaminathan, S., Awdew, R., Uyen T. Do, T., Boyd, R. S., Kaplan, A. J., Aud, D. M., Lin Lou, S., Trang, M., Foltz, I., Lynch, C. M., Terrett, J., Wilson, K. E., Rohlf, C., Manzin, S., Pellacani, A, Binaschi, M. MEN1309/OBT076, a first-in-class Antibody Drug Conjugate (ADC) targeting CD205 in solid tumors (2019) Mol Cancer Ther.18, 1533-1543

15. Diaz-Rodriguez, E., Pérez-Peña, J., Ríos-Luci, C., **Arribas, J.**, Ocaña, A., Pandiella, A. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells (2019) Cancer Letters 453, 34-44.

16. Gorbatenko, A., Søkilde, R., Sorensen, E. E., Newie, I., Persson, H.,Morancho, B.,**Arribas, J.**, Litman, T., Rovira, C., Pedersen, S. F. HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 (2019) Scientific Reports 9, 3352.

17. Blasco-Benito, S., Moreno, E., Seijo-Vila, M., Tundidor, I., Andradas, C. Caffarel, M. M., Caro-Villalobos, M., Urigüen, L., Diez-Alarcia, R., Moreno-Bueno, G., Hernández, L., Manso, L, Homar, P, McCormick, P. J., Bibic, L, Bernadó-Morales, C., **Arribas, J.**, Canals, M. Casadó, V. Canela, E. I., Guzmán, M., Pérez-Gómez, E., Sánchez, C. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (2019) Proc Natl Acad of Sci 116, 6505

18. Kang, S.-A., Guan, J. S., Tan, H. J., Thike, A. A., Bernadó Morales, C., **Arribas, J.**, Wong, C. Y., Tan, P. H., Judi, M., Putti, T. C., Sohn, J., Lim, S. H., Lee, S. C. and Lim, Y. P. Elevated WBP2 expression in HER2-positive breast cancers correlates with sensitivity to trastuzumab-based neo-adjuvant therapy:A Retrospective and Multicentric Study (2019) Clin Cancer Res 15, 2588-2600

19. Lambies, G., Miceli, M., Martínez-Guillamon, C., Olivera-Salguero, R., Atanassov, B. S., Dent, S. Y. R., **Arribas, J.**, García de Herreros, A., Díaz, V. M. The TGFβ-activated USP27X deubiquitinase regulates cell migration and chemo-resistance through Snail1 stabilization (2019) Cancer Res 79, 33-46.

2018

20. Rius Ruiz I, Vicario R, Morancho B, Bernadó Morales C, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V2, Rubio I, Cortés J, Serra V, Escriva-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M3, Saura C, Klein C, **Arribas J**. p95HER2-T Cell Bispecific Antibody for Breast Cancer Treatment (2018) Sci Transl Med 461, eaat1445.

21. Serrano, C., García-del-Muro, X., Valverde, C., Sebio, A., Durán, J., Manzano, A., Pajares, I., Hindi, N., Landolfi, S., Jiménez, L., Rubió-Casadevall, J., Estival, A., Lavernia, J., Safont, M. J., Pericay, C., Díaz-Beveridge, R., Martínez-Marín, V., Vicente-Baz, D., Vivancos, A., Hernández-Losa, J., **Arribas, J.***, Carles, J.* (2018) Clinicopathological and molecular characterization of metastatic gastrointestinal stromal tumors patients with prolonged benefit to frontline imatinib. Oncologist 2018 Aug 20. pii: theoncologist.2018-0032

Collaborations

22. Méndez, O. Peg , V., Salvans, C., Pujals, M., Fernández, Y.,Abasolo, I.,Pérez, J.,Matres, A.,Valeri. M.,Gregori, J.,Villarreal, J.,Schwartz Jr, S.,Ramon y Cajal, S.,Tabernero, J.,Cortés, J., **Arribas, J.**,Villanueva, J. Extracellular HMGA1 promotes Triple-Negative Breast Cancer Invasion and Metastasis by regulating tumor cell adhesion through RAGE signalling (2018) Clin Cancer Res 24, 6367-6382.

23. Cruz, C., Llop-Guevara, A., E. Garber, J. E., Arun, B. K., Pérez Fidalgo, J. A., Lluch, A., Telli, M. L., Fernández, C., Kahatt, C., Galmarini, C. M., Soto-Matos, A., Alfaro, V., Pérez de la Haza, A., Domcheck, S. M., Antolin, S., Vahdat, L., Tung, N. M., Lopez, R., **Arribas, J**., Vivancos, A., Baselga, J., Serra, V., Balmaña, J. & Isakoff, S. J. (2018) Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Sub-study (2018) J Clin Oncol 36, 3134-3143.

24. Georgilis, A., Klotz, S., Hanley, C. J., Herranz, N., Weirich, B., Morancho, B., Leote, A. C., D'Artista, L., Gallage, S., Seehawer, M., Carroll, T., Dharmalingam, G., Keng Boon, D. W, Mellone, M., Pombo, J., Heide, D., Guccione, E. ., **Arribas, J.**, Barbosa-Morais, N. L., Heikenwalder, M., Thomas, G. J., Zender, L. and Gil, J. PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells (2018) Cancer Cell 34, 85-102.

25. Serrano-Candelas, E., Ainsua-Enrich, E., Navinés-Ferrer, A., Rodrigues, P., García-Valverde, A., Bazzocco, S., Macaya, I., **Arribas, J.**, Serrano, C., Sayós, J., Arango., D. and Martin, M. (2018) Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth (2018) Molecular Oncology 12, 1383–1397.

26. Cruz, C., Castroviejo-Bermejo, M., Gutiérrez-Enríquez, S., Llop-Guevara, A., Ibrahim, Y. H., Gris-Oliver A., Bonache, S., Morancho, B., Bruna, A., Rueda, O. M. , Lai, Z., Polanska, U. M., Jones, G. N., Kristel, P., de Bustos, L., Guzman, M., Rodriguez, O., Grueso, J., Montalban, G., Caratú, G., Mancuso, F., Fasani, R., Jiménez, J., Howat, W. J., Dougherty, B., Vivancos, A., Nuciforo, P., Serres-Créixams, X., Rubio, I. T., Oaknin, A., Cadogan, E., Barrett, J. C., Caldas, C., Baselga, J., Saura, C., Cortés, J., **Arribas, J.**, Jonkers, J., Díez, O., O'Connor, M. J., Balmaña, J., Serra, V. (2018) RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer. Ann Oncol 29, 1203-1210.

27. Floros, K., Lochmann, T., Bin Hu, B., Monterrubio, C., Hughes, H., Wells, J., Bernadó Morales, C., Ghotra, M., Harada, H., Costa, C., Souers, A., Leverson, J., Tan, M., Serra, V., Koblinski, J., **Arribas, J.**, Miller, T., Dozmorov, M., Windle, B., Scaltriti, M. and Faber, A (2018) Co-amplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. Proc Natl Acad Sci 115:E2594-E2603.

28. Gawrzak, S., Rinaldi, L., Arenas, E. J., Salvador, F., Gregorio, S., Rojo, F., del Barco Barrantes, I., Cejalvo, J. M., Palafox, M., Guiu, M. , Berenguer-Llergo, A., Symeonidi, A., Urosevic, J., Bellmunt, A., Kalafatovic, D., Arnal-Estapé, A., Fernández, E., Müllauer, B., Groeneveld, R., Slobodnyuk, K., Stephan-Otto Attolini, C., Saura, C., **Arribas, J.**, Cortes, J., Ana Rovira, A., , Muñoz, M., Lluch, A., , Serra, V., Albanell, J., Prat, A., Nebreda, A. R., Aznar-Benitah, S. & Gomis, R. R. (2018) MSK1 regulates luminal cell differentiation and metastatic dormancy in breast cancer Nature Cell Biol 20, 211-221.

2017

29. Pedersen, K. Bilal, F., Bernadó Morales, C., Salcedo, M., Macarulla, T., Massó-Vallés, D., Mohan, V. Vivancos, A., Carreras, M.J., Serres, X., Abu-Suboh, M. Balsells, J., Allende E., Sagi, I., Soucek, L., Tabernero, T. and **Arribas J.** (2017) Pancreatic Cancer Heterogeneity and Response to anti-Mek Therapy. Oncogene 6, 5639-5647.

30. Morancho, B., Zacarías-Fluck, M., Esgueva, A., Bernadó Morales, C. Di Cosimo, S., Cortés , J., **Arribas, J.*** and Rubio, I. T.* (2016) Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget 7, 67956-67965. *Co-corresponding authors

---

Collaborations

31. Martín-Pérez, R., Yerbes, R., Mora-Molina, R., Cano- González, A., **Arribas, J.,** Mazzone, M., López- Rivas, A. and Palacios, C. (2017) Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. Oncotarget 8, 93688-93703.

32. Ríos-Luci , C., García-Alonso , S., Díaz-Rodríguez , E., Nadal-Serrano, M., **Arribas , J.**, Ocaña, A. and Pandiella, A. (2017) Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. Cancer Res 77, 4639-4651.

33. A Sabbaghi , M., Gil-Gómez , G., Guardia , C., Servitja , S., Arpi, O., García-Alonso, S., Menéndez, S., Arumi-Uria, M., Dr. Serrano, L., Salido, M., Muntasell, A., Martinez-Garcia, M., Zazo, S., Chamizo, C., González-Alonso, P., Madoz-Gúrpide, J., Eroles, P., **Arribas, J.**, Tusquets, I., Lluch, A., Pandiella , A., Rojo, F., Rovira A. and Albanell, J. (2017) Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin Cancer Res 23, 7006-7019.

34. Byrne, A. T., Alférez, A. G.,Amant, F., Annibali, D., **Arribas, J.**, Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., Clarke, R. B., Clevers, H., Coukos, G., Dangles-Marie, V., Eckhardt, S. G. , Gonzalez-Suarez, E. G. , Els Hermans, E, Hidalgo, M., Jarzabek, M., de Jong, S., Jonkers, J., Kemper, K., Lanfrancone, L., Mælandsmo, G. M., Marangoni, E., Marine, J.-C., Enzo Medico, E., Norum, J. H., Palmer, H. G., Peeper, D. S.,Pelicci, P.G., Piris, A., Roman-Roman, S., Rueda, O. M., Seoane, J., Serra, V., Soucek, L., Vanhecke, D., Villanueva, A., Vinolo, E., Bertotti, A., Trusolino, L. (2017) Interrogating open issues in cancer precision medicine using Patient- Derived Xenograft Models. Nature Rev Cancer 17, 254-268.

2016

35. Hutchinson, E., Pujana M. A. and **Arribas, J.** (2016) Cancer therapeutic resistance: progress and perspectives. Drugs of Today 52, 347-354.

Collaborations

36. Serra-Musach, J., Mateo, F., Capdevila-Busquets, E., de Garibay, G.R., Zhang, X., Guha, R., Thomas, C. J., Gureso, J., Villanueva, A., Jaeger, S., Heyn, H., Vizoso, M., Pérez, H., Cordero, A., Gonzalez-Suarez, E., Esteller, M., Moreno-Bueno, G., Tjärnberg, A., Lazaro, C., Serra, V., **Arribas, J.**, Benson, M., Gustafsson, M., Ferrer, M., Patrick Aloy, P. and Miguel Angel Pujana, M. A. (2016) Cancer network activity associated with therapeutic response and synergism. Genome Medicine 24, 88.

37. Esparís-Ogando, A., Montero, J. C., **Arribas, J.**, Ocaña, A. and Pandiella, A. (2016) Targeting the EGF/HER Ligand-Receptor System in Cancer. Curr Pharm Des 22, 5887-5898.

38. Hergueta-Redondo, M., Sarrio D, Molina-Crespo, Á, Vicario, R. Bernadó Morales, C. Martínez, L. Rojo-Sebastián, A., Serra-Musach, J., Mota, A., Martínez-Ramírez, A., Castilla, MÁ., González-Martin, A., Pernas, S., Cano, A. Cortes, J., Nuciforo, PG., Peg, V., Palacios, J., Pujana, MÁ., **Arribas, J**., and Moreno-Bueno, G. (2016). Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget 7, 56295-56308.

39. Nuciforo, P., Thyparambil, S., Aura, C., Garrido-Castro, A., Marta Vilaro, M., Peg, V. Jimenez, J. Hoos, W., Burrows, J., Todd Hembrough, T., Ferreres, J. C., Perez-Garcia, J., **Arribas, J.**, Cortes, J., and Scaltriti, M. (2015) High HER2 protein levels measured by multiplex mass spectrometry correlate with increased overall survival in patients treated with anti-HER2 therapy. Molecular Oncology 10, 138-147.

2015

40. Zacarias-Fluck, M., Morancho, B., Vicario, R., Luque-García, A., Escorihuela, M., Villanueva, J., Rubio, I. & **Arribas, J.** (2015) Effect of cellular senescence on the growth of HER2-positive breast cancers. J Natl Cancer Inst 107 (5): djv020

See editorial on the article: J Natl Cancer Inst (2015) 107(5): djv091

41. Morancho, B., Martínez-Barriocanal, A., Villanueva, J. and **Arribas, J.** (2015) Ectodomain shedding controls non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res 17, 106.

42. Vicario, R., Peg, V., Morancho, B., Zacarias-Fluck, M., Zhang, J., Martinez-Barriocanal, A., Navarro Jiménez, A., Aura, C., Burgues, O., Lluch, A., Cortés, J., Nuciforo, P., Rubio, I. T., Marangoni, E., Deeds, J., Boehm, M., Schlegel, R., Tabernero, J., Mosher, R., **Arribas, J.** (2015) Patterns of HER2 gene amplification and response to anti-HER2 therapies. PLoS One, 10(6):e0129876.

Collaborations

43. Massó-Vallés, D., Jauset, T., Serrano, E., Pedersen, K., Affara, N., Whitfield, J., Beaulieu, M. -E., Sodir, N., Evan, G. I., Elias, L., **Arribas, J.** and Soucek, L. (2015) Ibrutinib reduces fibrosis and improves the outcome of standard therapy in a preclinical model of pancreatic adenocarcinoma. Cancer Res 75, 1675-1681.

44. Scaltriti, M., Nuciforo, P., Bradbury. I, Sperinde, J., Agbor-Tarh, D., Chenna, A., Winslow, J., Serra, V., Parra, J.-Ll. Prudkin, I., Jimenez, J., Aura, C., Harbeck, N., Pusztai, L., Ellis, C., Eidtmann, H., **Arribas, J.**, Cortes, J., de Azambuja, E. Piccart, M. & Baselga, J. (2015) High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 21, 569-576.

2014

45. Parra-Palau, J. Ll., Morancho, B., Peg, P., Scaltriti, M., Vicario, R., Zacarias-Fluck, M., Pedersen, K., Pandiella, A., Nuciforo, P., Serra, V., Cortés, J., Baselga, J., M. Perou, C. M., Prat, A., Rubio, I & **Arribas J.** (2014) Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. J Natl Cancer Inst 106, dju291

See comment on the article in Cancer Discovery

46. Pedersen, K., Canals, F., Tabernero, J. and **Arribas, J.** PELO negatively regulates HER-receptor signaling and metastasis (2014) Oncogene 33, 1190-1197.

Collaborations

47. García-Parra, J., Arpí, O., Morancho, B., Dalmases, A., Menendez, S., Zazo, S., Chamizo C., Eroles, P., Servitja, S., Tusquets, I., Yelamos, J., Lluch, A., **Arribas, J.**, Rojo, F., Rovira, A. and Albanell, J. (2014) Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumor activity in HER2 overexpressing breast cancer Eur J Can 50, 2725-2734.

48. Gregori, J., Méndez, O., Katsila, T., Pujals, M., Salvans, C., Villarreal, L., **Arribas, J.**, Tabernero, J., Sánchez, A. and Villanueva, J. (2014) Enhancing the Biological Relevance of Secretome-based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. J Proteom Res 13, 3706–3721.

2013

49. Angelini, P. D., Zacarias-Fluck, M. F., Parra-Palau, J. Ll., Guiu, M., Pedersen, K., Bernadó Morales, C., Luque-García, A., Peiró Novalpotro, N., Giralt, J., Canals, F., Villanueva, J., Gomis, R. R., Baselga, J. and **Arribas, J.** (2013) Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res, 73, 450-458.

See comment on the article in Breast Cancer Res (2013) 15, 309

50. Morancho, B., Parra-Palau, J. Ll., Ibrahim, Y. H., Bernadó Morales, C., Bech-Serra, J. J., Pandiella, A., Canals, F., Baselga, J. and **Arribas, J.** (2013) A dominant negative N-terminal fragment of HER2 frequently expressed in breast cancers. Oncogene 32, 1452-1459

Collaborations

51. Serra, V., Vivancos, A., Puente, X. S., Felip, E., Silberschmidt, D., Caratu, G., Parra, J. L., De Mattos-Arruda, L., Grueso, J., Hernandez-Losa, J., **Arribas, J.**, Prudkin, L., Nuciforo, P., Scaltriti, M., Seoane, J., Baselga, J. (2013) Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation. Cancer Discov 3, 1238-1244.

52. Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. I., Prudkin, P., Sánchez, G., Rodríguez, O., Antón, P., Parra, J. Ll., Marlow, S., Scaltriti, M., Prat, A., **Arribas, J.**, Hahn, W. C., Kim, S. Y. and Baselga, J. (2013) RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 123, 2551-2563.

2012

53. Koziol, A., Gonzalo, P., Mota, A., Pollán, A., Lorenzo, C., Colomé, N., Montaner, D., Dopazo, J., **Arribas, J.**, Canals, F., Arroyo, A. G. (2012) The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells. FASEB J 26, 4481-4494.

2011

54. **Arribas, J.**, Baselga, J., Pedersen, K. and Parra-Palau, J. Ll. (2011) p95HER2 and breast cancer. Cancer Res 71, 1515-1519.

55. Malapeira, J., Esselens, C., Bech-Serra, J. J. Canals F., **Arribas J.** (2011) ADAM17 (TACE) regulates TGFbeta signaling through the cleavage of vasorin. Oncogene 30, 1912-1922.

Collaborations

56. Esteve, P., Sandonìs, A., Cardozo, M., Malapeira, J., Ibañez, C., Crespo, I., Gonzalez-Garcia, S., Marcos, S., Torribio, M. L., **Arribas, J.**, Shimono, A., Guerrero, I. and

Bovolenta, P. (2011) SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis. Nat Neurosci 14, 562-569.

57. Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., Gili, M., Russillo, M., Parra, J. Ll., Singh, S., **Arribas, J.**, Rosen, N., and Baselga, J. (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2 overexpressing breast cancer. Oncogene 30, 2547-2557.

2010

58. Parra-Palau, J. Ll., Pedersen, K., Peg, V., Scaltriti, M., Angelini, P. D., Escorihuela, M., Mancilla, S., Sánchez-Pla, A., Ramón y Cajal, S., Baselga, J., **Arribas, J.** (2010) A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the downmodulation of the ER in HER2-positive breast cancers. Cancer Res 70, 8537-8546.

59. **Arribas, J.**, Parra-Palau, J. L., Pedersen, K. (2010) HER2 fragmentation and breast cancer stratification. Clin Can Res 16, 4071-4073.

60. Esselens, C., Malapeira, J., Colome, N., Casal, C., Rodriguez-Manzaneque, J. C., **Canals, F.** and **Arribas, J.** (2010) The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J Biol Chem 285, 2463-2473.

Collaborations

61. Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., Gagnon, R., Koehler, M., Gomez, H., Geyer, C., Cameron, D., **Arribas, J.**, Rosen, N. and Baselga J. (2010) Clinical Benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor-2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 16, 2688-2695.

62. Chandarlapaty, S., Scaltriti, M., Angelini, P., Ye, Q., Guzman, M., Hudis, C. A., Norton, L., Solit, D. B., **Arribas, J.,** Baselga, J. and Rosen, N. (2010) Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29, 325-334.

2009-1990

63. Pedersen, K., Angelini, P.-D., Laos, S., Bach-Faig, A., Cunningham, M.-P., Ferrer-Ramón, C., Luque-García, A., García-Castillo, J., Parra-Palau, J.-Ll., Scaltriti, M., Ramón y Cajal, S., Baselga J. and **Arribas, J.** (2009) A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. Mol Cell Biol 29, 3319-3331.

Article Recommended by Faculty of 1000

64. García-Castillo, J., Pedersen, K., Angelini, P. D., Bech-Serra, J. J., Colome, N., Cunningham, M. P., Parra Palau, J. Ll., Canals, F., Baselga, J. and **Arribas, J.** (2009) HER2 carboxy terminal fragments regulate cell migration and cortactin phosphorylation. J Biol Chem 284, 25302-25313.

65. **Arribas, J.** and Esselens, C. (2009) ADAM17 as a Therapeutic Target in Multiple Diseases. Curr Pharm Des 15, 2319-2335.

66. Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. Ll., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., **Arribas, J.** and Baselga, J. (2009). Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 86, 803-814.

67. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., Maira, M., Garcia-Echeverria, C., Parra, J. Ll., **Arribas**, **J.** and Baselga, J. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents

PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68:8022-8030.

68. Vilar, E., Scaltriti, M., Balmana, J., Saura, C., Guzman, M., **Arribas**, **J.,** Baselga, J. and Tabernero J. (2008) Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer. 99,1607-1612.

69. Scaltriti, M., Rojo, F., Ocaña, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., **Arribas, J.**, & Baselga, J. (2007) p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 99, 628-638.

70. Esselens, C. W., Malapeira, J., Colome, N., Moss, M., Canals, F. and **Arribas, J.** (2008) Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. Biol Chem. 389, 1075-1084.

71. Santiago-Josefat, B., Esselens, C., Bech-Serra, J. J. and **Arribas, J.** (2007) Post-transcriptional upregulation of ADAM17 upon EGFR activation and in breast tumors. J Biol Chem 282, 8325-8331.

Article Recommended by Faculty of 1000

72. **Arribas, J**., Bech Serra, J. J. and Santiago-Josefat, B. (2006) ADAMs, cell migration and cancer Cancer Met Rev 25, 57-68.

73. Bech Serra, J. J., Santiago Josefat, B., Esselens C., Saftig, P., Baselga, J. **Arribas, J.*** and Canals, F. (2006) Proteomic Identification of Desmoglein-2 and ALCAM as substrates of ADAM17 and ADAM10 by Difference Gel Electrophoresis. Mol Cell Biol 26, 5086-5095 (* Corresponding autor).

74. Anido, J., Scaltriti, M., Bech Serra, J. J., Federico Rojo, F. Baselga, J. and **Arribas, J**. (2006) Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25, 3234-3244.

75. Zatovicova, M., Sedlakova, O., Svastova, E., Ohradanova, A., Ciampor, , F., **Arribas, J**., Pastorek, J. and Pastorekova, S. (2005) Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17 B J Cancer 93, 1267-1276

76. **Arribas J.** and Baselga, J. (2005) Who will benefit from anti-EGFR therapy? (2005) Lancet Oncol 6, 257-258.

77. **Arribas J**. (2005) Matrix metalloproteases and tumor invasion. New Eng J Med. 352, 2020-2021.

78. Martínez-Arca, S., Hurtando-Küttner, M., Borroto, A., and **Arribas, J.** (2005) Recycling of cell surface proTGF-alpha regulates EGFR activation. J Biol Chem 280, 36970-3697.

79. **Arribas, J.** and Ruiz-Paz, S. (2005) Regulation of ectodomain shedding. The ADAM Family of Metalloproteases. Edited by Hopper and Lendeckel. Kluwer plenum

80. Juanes, P. P., Ferreira, L., Montero, J. C., **Arribas, J**. and Pandiella. A. (2005) N-terminal cleavage of proTGF−alpha occurs at the cell surface by a TACE-independent activity. Biochem. J 389, 161-172.

81. Baselga, J. and **Arribas, J.** (2004) Treating cancer's kinase "addiciton". Nat Med 10, 786-787.

82. Helmke, B. M., Polychronidis, M., Benner, A., Thome, M., **Arribas, J.** and Deichmann, M. (2004) Melanoma metastasis is associated with enhanced expression of the syntenin gene Oncol Rep 12, 221-228.

83. Matar, P., Rojo, F., Cassia, R., Moreno-Bueno, G., Di Cosimo, S., Guzman, M., Rodriguez, S., **Arribas, J.**, Palacios, J., Baselga, J. (2004) Combined epidermal growth factor receptor (EGFR) targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 9, 1274-1283.

84. Villanueva de la Torre, T., Bech-Serra, J. J., Ruiz-Paz, S., Baselga, J., **Arribas, J.** (2004) Inactivating mutations block the Tumor Necrosis Factor-Alpha Converting Enzyme in the early secretory pathway Biochem Biophys Res Commun 314, 1028-1035.

85. Velasco-Loyden, G., **Arribas, J.**, López-Casillas, F. (2004) The shedding of Betaglycan is regulated by pervanadate and inhibited by TIMP-2. J Biol Chem 279, 7721-773.

86. Borroto, A., Ruíz-Paz, S., Borrell-Pagès, M., Villanueva de la Torre, T., Merlos-Suárez, A., Blobel, C. P., Baselga, J., and **Arribas, J.** (2003). Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. J Biol Chem. 278, 25932-25939.

87. Anido, J., Matar, P., Albanell, J., Guzman, M., Rojo, F., **Arribas, J.**, Averbuch, S. & Baselga, J. (2003). ZD1839 (Gefitnib), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2 overexpressing breast cancer cells. Clin Cancer Res 9, 1274-83.

88. Borrell-Pagès, M., Rojo, F., Albanell, J., Baselga, J., and **Arribas, J.** (2003) TACE is required for the activation of the EGFR by TGF-alpha in tumors, EMBO J 22, 1114-1124.

Article classified as “Must Read” by Faculty of 1000

89. **Arribas, J.** & Merlos-Suarez, A. (2003). Shedding of plasma membrane proteins. Curr Top Dev Biol 54,125-144.

90. **Arribas, J.** & Borroto, A. (2002). Protein Ectodomain Shedding. Chem Rev 102, 4627-4638.

91. Mayo, I., **Arribas, J.**, Villoslada, P., Alvarez DoForno, R., Rodriguez-Vilarino, S., Montalban, X., de Sagarra, M. R., and Castano, J. G. (2002). The proteasome is a major autoantigen in multiple sclerosis. Brain 125, 2658-2667.

92. Baselga, J., Albanell, J., Molina, M., and **Arribas, J.** (2001). Mechanism of action of trastuzumab and scientific update. Semin Oncol 28, 4-11.

93. Merlos-Suarez, A., Ruiz-Paz, S., Baselga, J., and **Arribas, J.** (2001). Metalloprotease-dependent Protransforming Growth Factor-alpha Ectodomain Shedding in the Absence of Tumor Necrosis Factor-alpha -converting Enzyme. J Biol Chem. 276, 48510-48517.

94. Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., **Arribas, J.**, and Baselga, J. (2001). Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells. Cancer Res 61, 4744-4749.

95. Velasco, G., Cal, S., Merlos-Suarez, A., Ferrando, A. A., Alvarez, S., Nakano, A., **Arribas, J.**, and Lopez-Otin, C. (2000). Human MT6-Matrix Metalloproteinase: Identification, Progelatinase A Activation, and Expression in Brain Tumors. Cancer Res 60, 877-882.

96. Rodriguez-Vilarino, S., **Arribas, J.**, Arizti, P., and Castano, J. G. (2000). Proteolytic Processing and Assembly of the C5 Subunit into the Proteasome Complex. J Biol Chem 275, 6592-6599.

97. Jesús M. Ureña, J. M., and **Arribas, J.** (2000). El transporte intracelular de proteínas. El caso del TGF-alfa. Ciencia al Dia Internacional 3, 1-14.

98. Borrell-Pages, M., Fernandez-Larrea, J., Borroto, A., Rojo, F., Baselga, J., and **Arribas, J.** (2000). The Carboxy-terminal Cysteine of the Tetraspanin L6 Antigen Is Required for Its Interaction with SITAC, a Novel PDZ Protein. Mol Biol Cell 11, 4217-4225.

99. Roghani, M., Becherer, J. D., Moss, M. L., Atherton, R. E., Erdjument-Bromage, H., **Arribas, J.**, Blackburn, R. K., Weskamp, G., Tempst, P., and Blobel, C. P. (1999). Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity. J Biol Chem. 274, 3531-3540.

100. Urena, J., Merlos-Suarez, A., Baselga, J., and **Arribas, J.** (1999). The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP). J Cell Sci 112, 773-784.

101. Fernández-Larrea, J., Merlos-Suárez, A., Ureña, J. M., Baselga, J., and **Arribas, J.** (1999). A Role for a PDZ Protein in the Early Secretory Pathway for the Targeting of proTGF-a to the Cell Surface. Mol Cell 3, 423-433.

102. Merlos-Suarez, A., and **Arribas, J**. (1999). Mechanisms controlling the shedding of transmembrane molecules. Biochem Soc Trans 27, 243-246.

103. Codony-Servat, J., Albanell, J., Lopez-Talavera, J. C., **Arribas, J.**, and Baselga, J. (1999). Cleavage of the HER2 Ectodomain Is a Pervanadate-activable Process That Is Inhibited by the Tissue Inhibitor of Metalloproteases-1 in Breast Cancer Cells. Cancer Res 59, 1196-1201.

104. Merlos-Suarez, A., Fernandez-Larrea, J., Reddy, P., Baselga, J., and **Arribas, J**. (1998). Pro-Tumor Necrosis Factor-alpha Processing Activity Is Tightly Controlled by a Component That Does Not Affect Notch Processing. J Biol Chem. 273, 24955-24962.

105. **Arribas, J.**, Lopez-Casillas, F., and Massague, J. (1997). Role of the Juxtamembrane Domains of the Transforming Growth Factor-alpha Precursor and the beta -Amyloid Precursor Protein in Regulated Ectodomain Shedding. J Biol Chem. 272, 17160-17165.

106. **Arribas, J**., Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S., and Massagué, J. (1996). Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors**.** J Biol Chem 271, 11376-11382.

107. Castano, J. G., Mahillo, E., Arizti, P., and **Arribas, J**. (1996). Phosphorylation of C8 and C9 subunits of the multicatalytic proteinase by casein kinase II and identification of the C8 phosphorylation sites by direct mutagenesis. Biochemistry 35, 3782-3789.

108. **Arribas, J**., and Massague, J. (1995). Transforming growth factor-alpha and beta-amyloid precursor protein share a secretory mechanism. J Cell Biol 128, 433-441.

109. **Arribas, J**., Arizti, P., and Castano, J. (1994). Antibodies against the C2 COOH-terminal region discriminate the active and latent forms of the multicatalytic proteinase complex. J Biol Chem 269, 12858-12864.

110. Ruiz de Mena, I., Mahillo, E., **Arribas, J**., and Castano, J. G. (1993). Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase. Biochem J 296, 93-97.

111. **Arribas, J**., and Castano, J. (1993). A comparative study of the chymotrypsin-like activity of the rat liver multicatalytic proteinase and the ClpP from Escherichia coli. J Biol Chem 268, 21165-21171.

112. Arizti, P., **Arribas, J.**, and Castano, J. G. (1993). Modulation of the multicatalytic proteinase complex by lipids, interconversion and proteolytic processing. Enzyme Protein 47, 285-295.

113. **Arribas, J**., Luz Rodriguez, M., Alvarez-Do Forno, R., and Castano, J. (1991). Autoantibodies against the multicatalytic proteinase in patients with systemic lupus erythematosus. J Exp. Med. 173, 423-427.

114. **Arribas, J**., and Castano, J. (1990). Kinetic studies of the differential effect of detergents on the peptidase activities of the multicatalytic proteinase from rat liver. J Biol Chem 265, 13969-13973.